The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Hosted on MSN4d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
Leerink Partners analyst Marc Goodman has maintained their bullish stance on MNMD stock, giving a Buy rating yesterday.Invest with Confidence: ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
How can you make therapy work best for you? Here are a few tips. And a new study offers more evidence that teens are in trouble.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback